House Committee Advances Bill to Restrict Chinese Biotech Firms’ Access to US Market

‘This bill is a necessary step towards protecting America’s sensitive healthcare data’ from the Chinese regime, Rep. James Comer said.

Rep. James Comer (R-Ky.) speaks during a press conference in the U.S. Capitol in Washington on April 30, 2024. Madalina Vasiliu/The Epoch Times

The House has advanced a bipartisan bill aimed at preventing U.S. taxpayer dollars from flowing to Chinese biotechnology firms that pose a national security threat.

The BIOSECURE Act (H.R. 8333) was approved by the House Oversight Committee on May 15 by a 40–1 vote. The bill would ban federal agencies from contracting any Chinese “biotechnology company of concern,” including Beijing Genomics Institute (BGI), MGI, Complete Genomics, WuXi Apptec, and WuXi Biologics.